These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23807520)

  • 21. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
    van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
    Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.
    Kuhadiya ND; Prohaska B; Ghanim H; Dandona P
    Diabetes Obes Metab; 2019 Apr; 21(4):1054-1057. PubMed ID: 30536789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].
    Penninga E; Færch K; Almdal T
    Ugeskr Laeger; 2011 Jun; 173(26):1863-9. PubMed ID: 21712007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
    Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
    Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
    Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
    J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
    Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D; Cummins E; Royle P; Waugh N
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
    van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM
    Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
    Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S
    Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
    Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
    Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
    Arakawa M; Ebato C
    Diabetes Metab Syndr; 2013; 7(4):223-5. PubMed ID: 24290089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.